Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC Internet ads

This article was originally published in The Tan Sheet

Executive Summary

FDA's Division of Drug Marketing, Advertising and Communication will issue a guidance on Internet promotions of prescription drugs shortly, DDMAC Director Minnie Baylor-Henry notes at the Drug Information Association annual meeting in Boston June 10. Without discussing the guidance specifically, Baylor-Henry indicates promotions that would be deemed violative for press releases would be considered similarly misleading on the Web. FDA is exploring "multiple remedies" for violative DTC promos, Baylor-Henry says, including warning letters, consent decrees, seizures and criminal prosecution. She also cautions companies against allowing their promotions departments to test the limits of legal DTC ads, advising that firms not use DDMAC "as a quality assurance checkpoint"...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088532

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel